Bradley Delaney

Business Development | Cell and Gene Therapy Innovation | Antibody Discovery | Preclinical Services for Biologics

Role: Business Development Manager at Nona Biosciences
Location: Boston, MA, US
LinkedIn followers: 500 followers

Sales & Business DevelopmentView LinkedIn profile

About Bradley Delaney

Cell biologist and immunologist focused in target validation and screening for novel biologics. Expertise in development and optimization of in-vitro/ex vivo cell-based assays for biopharmaceutical functional assessment. Passionate about increasing efficacy of novel biologics while lowering development and production costs for patients with high unmet medical needs.

Experience

Business Development Manager
Nona Biosciences
Sep 2025 — Present · Boston, MA, US
Drives partner relationships in monoclonal and bispecific antibody, ADC, cell & gene therapy development to provide high quality, fully human IgG and heavy chain-only antibody-based therapeutic candidates alongside services to support preclinical biologics development.

Education

Brown University
Biochemistry and Molecular Biology, Biotechnology
2017 — 2021
Northeastern University
Master of Science - MS, Biomedical Science
2023

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@nonabio.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Nona Biosciences

Biotechnology Research · 87 employees · Founded 2022 · Cambridge, Massachusetts, United States

Nona Biosciences is a biotechnology company advancing biotherapeutic discovery and development through proprietary antibody and modality-enabling technologies. Built on fully human antibody platforms, including Harbour Mice®, which generate both heavy chain-only (HCAb) and classical IgG (H2L2) antibodies, Nona enables high molecular diversity, strong developability, and broad therapeutic applicability. At the core of Nona’s technology ecosystem is Modalities-on-Demand™, a platform framework designed to enable the rapid conversion of antibody leads into diverse therapeutic formats. This includes bispecific and multispecific antibodies, T cell engagers, ADC and XDC formats, TCR-mimic antibodies, and CAR- and mRNA-based therapeutics. This modality-driven approach allows a single antibody foundation to be flexibly engineered across multiple architectures, supporting efficient program design and adaptability across evolving therapeutic strategies. These capabilities are further enhanced by Hu-mAtrIx™, Nona’s AI-driven platform for both discovery and development, which enables data-informed optimization across antibody generation, engineering, and translational workflows. By integrating AI with experimental platforms, Nona supports improved candidate selection, developability profiling, and accelerated progression through key development milestones. Together, these technologies support efficient progression within Nona’s I to I® framework, advancing programs from early concept and target validation through IND-enabling studies and toward clinical evaluation. Nona’s integrated capabilities span immunization, screening, engineering, and downstream development support, including pathways aligned with Investigator-Initiated Trials (IITs) and early clinical strategies through global partnerships.

nonabio.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Bradley Delaney

Experience

Business Development Manager

Education

Brown University

Northeastern University

Find verified contacts for anyone on LinkedIn